期刊
ANNALS OF MEDICINE
卷 43, 期 5, 页码 375-388出版社
TAYLOR & FRANCIS LTD
DOI: 10.3109/07853890.2011.572905
关键词
Antiretroviral therapy; HIV; protease inhibitors; ritonavir
资金
- Ministry of Health Services
- Ministry of Healthy Living and Sport
- Province of British Columbia
- Canadian Institutes of Health Research (CIHR)
- National Institute of Drug Abuse, at the US National Institutes of Health [1DP1DA026182-01]
The advent of combination antiretroviral therapy has led to significant improvement in the care of HIV-infected patients. Originally designed as a protease inhibitor (PI), ritonavir is currently exclusively used as a pharmacokinetic enhancer of other protease inhibitors, predominantly due to ritonavir's potent inhibition of the cytochrome P450 3A4 isoenzyme. Ritonavir-boosting of PIs decrease pill burden and frequency of dosing. Boosted PIs are recommended for first-line therapy in treatment and play a key role in the management of treatment-experienced patients. Potential problems associated with PIs include metabolic abnormalities (e.g. dyslipidemia), increased cardiovascular risk, and drug interactions.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据